ISSCR News


‍The International Stem Cell Research Community Convenes in Montréal as ISSCR 2026 Opens with Visionary Science and Global Collaboration
Press Release Kym Kilbourne Press Release Kym Kilbourne

‍The International Stem Cell Research Community Convenes in Montréal as ISSCR 2026 Opens with Visionary Science and Global Collaboration

The International Society for Stem Cell Research (ISSCR) today opened its 2026 Annual Meeting in Montréal, bringing together thousands of scientists, clinicians, industry leaders, regulators, trainees, and patient advocates from around the world for four days of scientific discovery, collaboration, and innovation across the stem cell field.

‍Co-sponsored by STEMCELL Technologies, ISSCR 2026 showcases the full spectrum of stem cell research from fundamental discoveries in developmental biology to emerging clinical advances, disease modeling, regenerative medicine, gene editing, and new technologies that are shaping the future of biomedical science.

Read More
Encellin Announces New Phase 1 Clinical Progress at ISSCR 2026 Showing Early Evidence of Non-Fibrotic Engraftment of Cell Therapy Implant for Type 1 Diabetes
Press Release Kym Kilbourne Press Release Kym Kilbourne

Encellin Announces New Phase 1 Clinical Progress at ISSCR 2026 Showing Early Evidence of Non-Fibrotic Engraftment of Cell Therapy Implant for Type 1 Diabetes

Encellin today announced new clinical progress from its ongoing Phase 1 study evaluating its implantable cell therapy platform for people with type 1 diabetes. The company made the announcement in connection with the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting, reporting non-fibrotic engraftment across all seven participants enrolled in the trial, along with host vascularization at the implant site and identification of transplanted islets in multiple participants. The findings build upon interim results first reported in January 2026 and reflect a larger patient cohort, with analysis of the full clinical dataset ongoing.

Read More
Vascular Organoid Patches Offer New Hope for Coronary Artery Disease Treatment  
Press Release Kym Kilbourne Press Release Kym Kilbourne

Vascular Organoid Patches Offer New Hope for Coronary Artery Disease Treatment  

Ischemic heart disease (IHD), also known as coronary artery disease, is a leading cause of death and morbidity in western countries. IHD arises when blood vessels of the heart become clogged, blunting oxygen and nutrient supply to heart muscle cells, which eventually die off, leading to heart attack or heart failure.  Although larger blood vessels can be replaced surgically to restore blood flow, there is currently no treatment targeting smaller blood vessels, so-called microvessels, which are essential for the uniform blood circulation within the heart muscle. 

Yasuhiro Shudo and his team from Stanford University, USA have tested a method to regenerate microvessels in the heart with stem cell-derived vascular organoids. Their work was published today in Stem Cell Reports.

Read More
High Fructose During Pregnancy Impairs Stem Cell Function in the Fetal Brain
Press Release Kym Kilbourne Press Release Kym Kilbourne

High Fructose During Pregnancy Impairs Stem Cell Function in the Fetal Brain

Nutritional imbalance during pregnancy can have long-lasting effects on the health status and disease susceptibility of the offspring. As such, high fructose intake through sweetened food and beverages in pregnant women has been associated with an increased susceptibility to diabetes and cardiovascular disease, as well as neurological and cognitive impairments in the offspring. Currently, it is not well understood how early life exposure to fructose has such long-lasting effects on the cellular and molecular level.  

In a recent paper published in Stem Cell Reports, Hiroya Yamada’s team from Fujita Health University School of Medicine, Toyoake, Japan found that the performance of adult rats in learning and memory tests was impaired when the rats had been exposed to high fructose in before birth by feeding their mothers with high fructose corn syrup

Read More
Bayer Named Founding Member of the ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development
Press Release Kym Kilbourne Press Release Kym Kilbourne

Bayer Named Founding Member of the ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development

The International Society for Stem Cell Research (ISSCR) announces today that Bayer is a Founding Member of the ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development, a global cross-sector initiative focused on accelerating the responsible integration of human stem cell-derived models into preclinical drug development.

‍Co-chaired by Daniela Cornacchia, AstraZeneca, USA, and Shuibing Chen, Weill Cornell Medicine, USA, the consortium is leading a coordinated international effort to advance the regulatory qualification and adoption of human stem cell-derived models, including organoids, engineered tissues, and microphysiological systems, as New Approach Methodologies (NAMs) for drug discovery and development.

Read More

Receive ISSCR Press Releases

Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications

Subscribe to ISSCR News.

Each month, ISSCR delivers scientific, policy, and community to your inbox .